Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+
from Treatment with Lynparza
More Than 20,000 Patients in Japan Now Qualify for Genetic Testing
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis
® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect.